Unlocking the Potential of Disulfidptosis: Nanotechnology-Driven Strategies for Advanced Cancer Therapy

Area of Science:

• Oncology
• Cell Biology
• Nanotechnology

Background:

• Tumor tissues exhibit heightened oxidative stress.
• The cystine-glutamate transporter xCT/SLC7A11 (solute carrier family 7 member 11) is crucial for cancer cell survival by enabling cystine uptake for glutathione synthesis.
• Disulfidptosis is a programmed cell death (PCD) pathway observed in cells with high xCT/SLC7A11 expression under glucose deprivation.

Purpose of the Study:

• To explore the mechanisms of disulfidptosis.
• To evaluate its therapeutic potential in cancer treatment.
• To investigate the synergistic role of nanotechnology in enhancing disulfidptosis-induced cancer cell death.

Main Methods:

• Review of existing literature on disulfidptosis, xCT/SLC7A11 function, and nanotechnology applications in cancer therapy.
• Analysis of how nanomaterials can induce reactive oxygen species (ROS) and disrupt disulfide bonds.
• Exploration of combining disulfidptosis with ROS-induced immunogenic cell death for enhanced anti-tumor immunity.

Main Results:

• Disulfidptosis is characterized by aberrant disulfide bond formation and cellular dysfunction, leading to cancer cell death.
• Nanomaterials can be engineered to induce ROS generation and deliver therapeutic agents selectively to tumors.
• Combining disulfidptosis with ROS-induced immunogenic cell death can remodel the tumor microenvironment and boost anti-tumor immunity.

Conclusions:

• Disulfidptosis represents a novel therapeutic vulnerability in cancer, particularly in cells reliant on xCT/SLC7A11.
• Nanotechnology offers a powerful platform for selectively inducing disulfidptosis and improving cancer treatment efficacy.
• Targeting disulfidptosis with nanomaterials presents a promising strategy for developing more effective, selective, and less toxic cancer therapies.